BACKGROUND AND PURPOSE: Collateral flow augmentation using partial aortic occlusion may improve cerebral perfusion in acute stroke. We assessed the safety and feasibility of partial aortic occlusion immediately after intravenous tissue plasminogen activator. METHODS: We conducted an open-label pilot study of partial aortic occlusion after thrombolysis. The primary end point was all serious adverse events within 30 days of treatment. RESULTS: None of the 22 patients enrolled developed symptomatic parenchymal hemorrhages. Asymptomatic hemorrhagic transformation occurred in 9 patients. Procedure-related adverse events were limited to groin complications (n=13). Seventy-seven percent of patients experienced neurological improvement (≥4-point improvement of the National Institutes of Health Stroke Scale score). CONCLUSIONS: Partial aortic occlusion as an adjunct to thrombolysis in the treatment of acute stroke appears safe. Studies aimed at determining the efficacy of this therapeutic approach are warranted. CLINICAL TRIAL REGISTRATION INFORMATION: URL: http://www.clinicaltrials.gov. Unique Identifier: NCT01006993.
BACKGROUND AND PURPOSE: Collateral flow augmentation using partial aortic occlusion may improve cerebral perfusion in acute stroke. We assessed the safety and feasibility of partial aortic occlusion immediately after intravenous tissue plasminogen activator. METHODS: We conducted an open-label pilot study of partial aortic occlusion after thrombolysis. The primary end point was all serious adverse events within 30 days of treatment. RESULTS: None of the 22 patients enrolled developed symptomatic parenchymal hemorrhages. Asymptomatic hemorrhagic transformation occurred in 9 patients. Procedure-related adverse events were limited to groin complications (n=13). Seventy-seven percent of patients experienced neurological improvement (≥4-point improvement of the National Institutes of Health Stroke Scale score). CONCLUSIONS: Partial aortic occlusion as an adjunct to thrombolysis in the treatment of acute stroke appears safe. Studies aimed at determining the efficacy of this therapeutic approach are warranted. CLINICAL TRIAL REGISTRATION INFORMATION: URL: http://www.clinicaltrials.gov. Unique Identifier: NCT01006993.
Authors: Bijoy K Menon; Billy O'Brien; Andrew Bivard; Neil J Spratt; Andrew M Demchuk; Ferdinand Miteff; Xuewen Lu; Christopher Levi; Mark W Parsons Journal: J Cereb Blood Flow Metab Date: 2012-11-14 Impact factor: 6.200
Authors: Peter D Schellinger; Martin Köhrmann; Songling Liu; William P Dillon; Raul G Nogueira; Ashfaq Shuaib; David S Liebeskind Journal: Stroke Date: 2013-04-02 Impact factor: 7.914
Authors: P D Schellinger; A Shuaib; M Köhrmann; D S Liebeskind; T Jovin; M D Hammer; S Sen; D Y Huang; S Solander; R Gupta; R R Leker; J L Saver Journal: AJNR Am J Neuroradiol Date: 2013-07-04 Impact factor: 3.825
Authors: Hans T H Tu; Bruce C V Campbell; Soren Christensen; Patricia M Desmond; Deidre A De Silva; Mark W Parsons; Leonid Churilov; Maarten G Lansberg; Michael Mlynash; Jean-Marc Olivot; Matus Straka; Roland Bammer; Gregory W Albers; Geoffrey A Donnan; Stephen M Davis Journal: Int J Stroke Date: 2013-03-12 Impact factor: 5.266
Authors: Ronen R Leker; Carlos Molina; Kevin Cockroft; David S Liebeskind; Mauricio Concha; Ashfaq Shuaib; Peter Paul De Deyn; W Scott Burgin; Rishi Gupta; William Dillon; Hans-Christoph Diener Journal: Cerebrovasc Dis Date: 2012-10-11 Impact factor: 2.762